Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Operations: 2013-2024

Historic Cash from Operations for Collegium Pharmaceutical (COLL) over the last 12 years, with Dec 2024 value amounting to $205.0 million.

  • Collegium Pharmaceutical's Cash from Operations rose 971.63% to $78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $290.9 million, marking a year-over-year increase of 50.21%. This contributed to the annual value of $205.0 million for FY2024, which is 25.39% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Cash from Operations of $205.0 million as of FY2024, which was down 25.39% from $274.7 million recorded in FY2023.
  • Over the past 5 years, Collegium Pharmaceutical's Cash from Operations peaked at $274.7 million during FY2023, and registered a low of $93.9 million during FY2020.
  • Its 3-year average for Cash from Operations is $201.3 million, with a median of $205.0 million in 2024.
  • In the last 5 years, Collegium Pharmaceutical's Cash from Operations soared by 238.13% in 2020 and then declined by 25.39% in 2024.
  • Collegium Pharmaceutical's Cash from Operations (Yearly) stood at $93.9 million in 2020, then grew by 10.24% to $103.6 million in 2021, then grew by 19.96% to $124.2 million in 2022, then surged by 121.16% to $274.7 million in 2023, then dropped by 25.39% to $205.0 million in 2024.